Existing drugs can sometimes be repurposed to treat rare diseases. But making that match can be hard — and the financial incentives are weak. Guest host Steve Levitt tries to solve the puzzle.
SOURCES:
Chris Snyder, professor of economics at Dartmouth College.
David Fajgenbaum, co-founder and president of Every Cure, physician-scientist at the University of Pennsylvania.
Heather Stone, health science policy analyst at the Food & Drug Administration.
Sarrin Chethik, senior policy analyst at the Market Shaping Accelerator.
RESOURCES:
Chasing My Cure: A Doctor's Race to Turn Hope into Action; A Memoir, by David Fajgenbaum (2019).
Strong Medicine: Creating Incentives for Pharmaceutical Research on Neglected Diseases, by Michael Kremer and Rachel Glennerster (2016).
Market Shaping Accelerator.
CURE ID Registry.
Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
Плейлист
Freakonomics Radio
Existing drugs can sometimes be repurposed to treat rare diseases. But making that match can be hard — and the financial incentives are weak. Guest host Steve Levitt tries to solve the puzzle.
SOU...
When Richard Thaler first published Nudge, the world was just starting to believe in his brand of behavioral economics. In this 2021 episode, we ask: How has nudge theory held up in the face of a glob...
The science says no, at least not in the athletic sense. But the psychic benefits can be large — just ask former N.F.L. star Ricky Williams. He says athletes should consider cannabis a healing drug, n...
In sports, the rules are meant to be sacrosanct. But when it comes to performance-enhancing drugs, the slope is super-slippery. (Part one of a two-part series.) SOURCES:April Henning, associate profes...
They used to be the N.F.L.’s biggest stars, with paychecks to match. Now their salaries are near the bottom, and their careers are shorter than ever. In this updated episode from 2025, we speak with a...
For 50 years, the healthcare industry has been trying (and failing) to harness the power of artificial intelligence. It may finally be ready for prime time. What will this mean for human doctors — and...
Zeke Emanuel (a physician, medical ethicist, and policy wonk) has some different ideas for how to lead a healthy and meaningful life. It starts with ice cream. (Part three of “The Freakonomics Radio G...
After five years, Levitt is ending People I (Mostly) Admire, and will start hosting the occasional Freakonomics Radio episode. We couldn’t be happier. SOURCES:Steve Levitt, co-author of Freakonomics a...
It regulates 20 percent of the U.S. economy, and its commissioner has an aggressive agenda — faster drug approvals, healthier food, cures for diabetes and cancer. How much can he deliver? (Part two of...
We all want to stay sharp, and forestall the cognitive effects of aging. But do brain supplements actually work? Are they safe? And why doesn’t the F.D.A. even know what’s in them? (Part one of “The F...
One Yale economist certainly thinks so. But even if he’s right, are economists any better? We find out, in this update of a 2022 episode. SOURCES:James Choi, professor of finance at the Yale School of...
Behavioral scientists have been exploring whether a psychological reset can lead to lasting change. In this update of a 2021 episode, we survey evidence from the London Underground, Major League Baseb...
A series of academic studies suggest that the wealthy are, to put it bluntly, selfish jerks. It’s an easy narrative to embrace — but is it true? As part of GiveDirectly’s “Pods Fight Poverty” campaign...
All sorts of people have put their mark on Messiah, and it has been a hit for nearly 300 years. How can a single piece of music thrive in so many settings? You could say it’s because Handel really kne...
In the 18th century, Handel relied on royal patronage. Today, it’s donors like Gary Parr who keep the music playing. In this bonus episode of our “Making Messiah” series, Parr breaks down the economic...